AZNAstraZenecaRunning, no new patients
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
Neurofibromatosis Type 1
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 36 (final count)
- Started
- Jan 21, 2022
- Main results expected
- Nov 30, 2027
- Fully finished
- Apr 28, 2028
- Results posted
- May 14, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Selumetinib AUC0-12 Derived After Single Dose Administration
Measured over: Pre-dose and 1, 2, 3, 4, 6, 8 and 10-12 hours after selumetinib single dose on the first day of study treatment (Cycle 1 Day 1) (each cycle is 28 days)
Adverse Events Graded by CTCAE Ver 5.0
Measured over: from screening until 30 days after last dose
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05309668 · record last updated 2026-08-13 · checked 2026-11-09 15:47 UTC